MGC Pharmaceuticals Ltd.
PDMR Notification
28 March 2024
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) were issued a combined 240,000 unlisted options as approved at a meeting of shareholders on 18 March 2024. This notification is made in accordance the UK Market Abuse Regulations.
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Daniel Robinson | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Non-Executive Director | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.42 on or before 28 March 2027. | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.00 | 120,000 | N/A | |
| | Aggregated information | ||||
| | AUD | 0.00 | 120,000 | N/A | |
| (e) | Date of transaction
| 28 March 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Layton Mills | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Non-Executive Director | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Unlisted options exercisable at A$0.42 on or before 28 March 2027. | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Grant of Options over Ordinary Shares | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | 0.00 | 120,000 | N/A | |
| | Aggregated information | ||||
| | AUD | 0.00 | 120,000 | N/A | |
| (e) | Date of transaction
| 28 March 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
-Ends-
Authorised for release by the Company Secretary, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6555 2950 | MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6555 2950
|
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.